Background: Vaginal metastases originating from colorectal carcinoma are very rare. Due to the limited number of reported cases, there is no proposed standard treatment and little is known about its management outcome. Aim: The aim of this article is to review the available literature to establish the clinical presentation, trends in treatment and prognosis of vaginal metastases from colorectal malignancy. Methods: A literature search using keywords used for database search were 'colorectal carcinoma', 'colorectal cancer', 'colon cancer' and 'vaginal metastasis'. Results: Of the 30 articles identified, 37 reported cases, were accessible for full evaluation. Cases reported originates from various countries and majority presented with vaginal bleeding. Diagnosis was established after histological examination and treatment options consist of surgical resection, radiotherapy or chemotherapy that have been used individually or in combination. Association with disseminated metastatic disease indicates ominous prognosis as seen in 32.4% (n ¼ 12) cases.
Introduction
Colorectal cancer is one the most common types of cancer in Western countries. In the United States of America, it ranks fourth as cause of cancer. The most frequent sites for systemic spread are the liver and lungs. More rarely, the disease spreads to the brain or bones. However, metastases from colorectal cancer to the vagina are extremely rarely reported. More frequently, vaginal involvement in colorectal cancer occurs by direct contiguous spread from the primary tumour. To date, only 49 cases of vaginal metastasis from colorectal cancer have been reported in 30 articles. 1e30 Whitelaw et al. 1 published the first report of vaginal metastasis from colorectal cancer in 1956, which was a case of vaginal lesion from sigmoid adenocarcinoma. The second report was in 1966 by Raider, which included a series of four cases of vaginal adenocarcinoma from colon cancer were presented. The vaginal lesions were diagnosed between 4 and 41 months after colonic resection and in three of the four cases, the overall survival was less than 40 months due to metastasis to other organs. 2 Cases of vaginal metastases from colorectal cancer continue to be rare or possibly under-reported. These lesions often present a diagnostic & therapeutic challenge and due to the limited number of reported cases, there is no proposed standard treatment and little is known about its management outcome.
To date, all the published literature on vaginal metastases from colorectal cancer consist of case reports only with limited guidance to assist clinicians faced with patients with such rare, but clinically important, condition. The aim of this article is to review the available literature to establish the clinical presentation, trends in treatment and prognosis of vaginal metastases from colorectal malignancy.
Methods
A literature search using PubMed and Ovidsp, which includes database of Embase, EBM reviews, Medline, CAB Abstracts and AMED was performed. Keywords used for database search were 'colorectal carcinoma', 'colorectal cancer', 'colon cancer' and 'vaginal metastasis'.
The search had no limitation on study type, period of publication or language. A further search for additional case reports from the reference lists provided by the identified articles was done. Duplicates were removed and the abstracts of the selected titles were screened for eligibility. Inclusion criteria were all articles 
Clinical presentation
Case reports of 37 cases were analysed in this review ( Table 2 ). The average age at the time of presentation was 60.6 years, with a range of 43 yearse83 years. The majority of patients (51.4%, n ¼ 19) presented with vaginal bleeding. However, 5.4% (n ¼ 2) presented with vaginal discharge, 2.7% (n ¼ 1) presented with vaginal staining, 10.8% (n ¼ 4) presented with vaginal mass and 2.7% (n ¼ 1) presented with perineal discomfort. A total of 10.8% (n ¼ 4) did not have gynaecological or colorectal symptoms, but were found to have vaginal mass during routine gynaecological examination in 5.4% (n ¼ 2) and after a follow-up CT scan for ovarian cancer in another 5.4% (n ¼ 2). Interestingly, 27% (n ¼ 10) of the reported cases in the literature were without known previous history of colorectal carcinoma. These patients presented with vaginal symptoms and metastatic colorectal cancer was diagnosed after biopsy of the vaginal lesion. In 16.2% (n ¼ 6) of cases, there was no mention of the presenting complaint (Fig. 2) .
Diagnosis
Of the 37 accessible reported cases, 97.3% (n ¼ 36) were diagnosed as vaginal metastasis of colorectal carcinoma after biopsy & histological examination and 2.7% (n ¼ 1) was diagnosed by liquid based cytology and immunochemistry study.
Treatment
Therapeutic options for the vaginal lesion were surgical resection, radiotherapy and chemotherapy used individually or in combination. Surgical resection as the only treatment were reported in 21.6% (n ¼ 8) of the cases, 18.9% (n ¼ 7) were treated with surgical resection and radiotherapy and 13.5% (n ¼ 5) were treated with surgical resection and chemotherapy. Radiotherapy was used as the only treatment for 13.5% (n ¼ 5) while 2.7% (n ¼ 1) had chemotherapy as the only treatment. Combination of radiotherapy and chemotherapy were used in 8.1% (n ¼ 3) and 10.8% (n ¼ 4) had surgical resection, chemotherapy as well as radiotherapy as treatment. There were 10.8% (n ¼ 4) of case reports where the treatment for the vaginal mass was not mentioned (Fig. 3) . Overall, the use of chemotherapy was reported in 11 articles 6,9,10,13,18,20,23,25e27,29 , however most of the articles did not specify the exact nature of the chemotherapeutic agent used or the duration of the treatment. Chemotherapeutic agents used were 5-fluorouracil 13 as well as fluoropyridine and MFOLFOX6. 29 There were three case reports 13, 27, 29 that involved single agent chemotherapy while another two case reports 18, 23 involved combination of chemotherapy agents as treatment. The single chemotherapy agent that were used included fluorouracil (5FU), 13 irinotecan, 27 fluoropyridine and NFOLFOX 29 while combination chemotherapy agents included oxaliplatin with capecitabine 23 and fluorouracil (5FU) with calcium leucovorin. 18 There were six case reports 6,9,10,20,25,26 that did not mention the chemotherapy agent.
Prognosis
It was difficult to ascertain the overall prognosis or survival as such data were not universally available so we had to rely on survival at the time of writing the case report, which gives relatively limited insight on the true prognosis in these patients. Taking this into account, 21.6% (n ¼ 8) of patients who presented with no other metastases, apart from the vaginal metastases, and had resection of the primary carcinoma where all were free of disease and had no recurrence reported after treatment for the vaginal metastasis at the time of case report. On the other hand, 2.7% (n ¼ 1) of cases reported with no other metastases besides to the vagina had recurrence after having radiotherapy as the only treatment but was still alive at the time of report. Also, there were 29.7% (n ¼ 11) of reported cases were alive at the time of case report even with presence of metastases to other organs.
Control of the metastases was achieved by tumorectomy and administration of adjuvant therapy such as chemotherapy and radiotherapy. As seen in most of the reported cases, association with disseminated metastatic disease indicates ominous prognosis. There were 32.4% (n ¼ 12) who had limited survival due to the metastases to other organs with two died of brain metastasis. There were no mention about survival after vaginal lesion was diagnosed in 13.5% (n ¼ 5).
Discussion
Primary vaginal carcinomas are very uncommon and it accounts for only 2% of all malignant lesions of female genital system. 31 They are most commonly squamous cell carcinomas (86%), very rarely adenocarcinoma (8%) or other histological types (7%). The majority of vaginal adenocarcinomas are often secondary to uterine Embase, EBM reviews, Medline, CAB Abstracts, AMED and article's adenocarcinoma, rarely to other tumours such as kidney, breast or pancreas. 19 When colorectal cancer metastasizes to the female genital tract, ovaries are the most frequent site followed by vagina and endometrium. 4 Therefore, vaginal metastases from colorectal cancer are relatively rare with limited number of cases reported in the literature. Consequently, there is neither consensus on the surgical treatment nor a clear policy on the use of chemotherapy and/or radiotherapy. The majority of the reported cases of vaginal metastasis from colorectal cancer originate from primary tumours located in the rectum or sigmoid colon. It is well known that there are subtle variations in the technique of rectal cancer surgery resection across the world, in particular regarding the routine use of rectal washout which is thought to reduce viable tumour cells in the rectal stump that might, theoretically, result in local tumour implantation. It was not possible from the reported literature to determine if these patients had rectal washout at the time of surgical resection of their primary. The fact that there are reports from various countries across the world make it less convincing that variations in surgical technique would account for developing vaginal metastases by tumour implantation at the time of surgery.
However, the limited number of cases makes it difficult to reach definite conclusions.
Four mechanisms of spread of colorectal cancer to the vagina have been proposed. The first suggested route of spread is by local invasion where direct extension of the primary tumour occurs through the ischiorectal fossa and junction of the deep and superficial perineal membranes. 19 However, this route is not possible for vaginal metastasis from other primaries at distant sites such as breast carcinomas. The second proposed course of spread is via transcoelomic route where tumour cells could be implanted in the Fallopian tube or uterus and subsequently to the vagina. 19 Given that some of the patients in the reported cases had hysterectomy before the metastasis, this theory is not strongly agreed upon. The other two suggested metastatic routes are lymphatic and haematogenous spread. 2 For lymphatic spread, there is a possibility of metastasis from the sigmoid colon lymphatics to the iliac and hypogastric lymph nodes where retrograde spread to the periurethral area and anterior vaginal wall occur. 21 Also, it is recognized that there is communication between posterior vaginal wall and rectal lymphatics. Therefore, it has been suggested that retrograde spread may also occur from the rectal lymph nodes. This view is not universally accepted, as there are few reported cases of vaginal metastases from lymph node negative colorectal tumours. As for haematogenous route, venous channels may allow metastatic cells to travel from the primary site in the colon to the ovarian plexus or parametrial veins and then to the vaginal veins. 2 This last hypothesis seems the most appropriate route to explain vaginal metastases from colorectal cancer. However, it should be acknowledged that there are many uncertainties regarding the available case reports on vaginal metastases as most of the available articles did not explicitly state if the lesions were thought to be related to haematogenous or lymphatic metastases rather than "drop metastases" or direct extension. Presentation of colorectal cancer with vaginal bleeding is atypical and very rare. Some of the reported cases 1, 5, 6, 10, 11, 13, 17, 19, 20, 23 presented with vaginal bleeding and were diagnosed with the vaginal metastases before the colorectal primary lesion was diagnosed. Therefore, biopsy and thorough histopathological evaluation is vital to determine the site of origin of the lesion. Besides that, female patients with history of rectal or sigmoid carcinoma that present with vaginal bleeding or sensation of a lump in the vagina should have an urgent gynaecological examination to exclude local metastasis.
There is no agreement on the management of vaginal metastases from colorectal cancer. Management options that were documented in these reported cases comprised of local excision of 23,27,29 also had adjuvant therapy by means of chemotherapy or radiotherapy with good overall survival. Hence, it seems that adjuvant therapy following resection of vaginal metastases could potentially offer some survival benefit as shown by the 27% (n ¼ 10) of cases that received adjuvant therapy. However, due to the limited number of reported cases and variation as well as lack of details of the adjuvant therapy regimens used it would be difficult to be certain of this recommendation. It should be noted that this review has several limitations as it mainly relies on case reports with variable quality as well as limited number of cases. Also, there could be reporting bias of vaginal metastases from colorectal cancer with cases under-reported, misdiagnosed or tendency to report cases with more favourable outcome. Consequently, the actual incidence, response to treatment, survival as well as the outcome might be different from what could be established from the available literature.
This review emphasizes the paucity of evidence in the current literature that might increase the awareness with the condition and encourage reporting similar cases in the future. Also, highlighting the limitations in the currently available case reports might improve the quality of data included in future publications.
Due to the limitations we have encountered in constructing evidence from the available literature in this review, we recommend that future case report should include data pertaining to site of the colorectal primary, mode of presentation of the vaginal metastasis from colorectal cancer, how was the diagnosis established and details of any surgical treatment offered. It would also be vital to include detailed information on radiotherapy or chemotherapy treatment with exact duration and dosage. Data related to survival could be more difficult to report accurately as most of the case reports are made following the diagnosis rather than patient's death.
Nevertheless, this review would be a useful tool for clinicians faced with this rare condition to be aware of the various treatment modalities that have been used in the past, to guide them on the various options in management and give some insight on the prognosis.
Conclusion
Vaginal metastases from colorectal cancer should be included in the differential diagnosis in patients presenting with vaginal bleeding or sensation of a vaginal swelling. When such presentation occurs in patients with history of colorectal carcinoma, a thorough gynaecological assessment should be done. Even though there is no consensus on treatment, this review highlights that the available limited evidence suggests that isolated vaginal metastasis from colorectal cancer that is amenable to local surgical resection has reasonable outcome. Also, evidence suggests that adjuvant therapy would be a rational adjunct. However, vaginal metastasis from colorectal cancer in the context of diffuse metastatic disease portends poor prognosis.
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